Stakeholders’ Consulting Group

ICE-HBV collaborates with key stakeholders to accelerate research in HBV cure. ICE-HBV Stakeholders’ Consulting Group gathers them annually to provide input on the development of ICE-HBV global research roadmap, share information about HBV cure programmes and identify potential synergies and collaborations areas.

The Stakeholders’ Consulting Group provides advice to researchers working towards the discovery of a safe, affordable, scalable and effective Hepatitis B cure.

The group is working on the following three pillars of HBV Cure preparedness, to ensure the timely and effective transition of research discoveries:

Health Policy (Gap Analysis and Investment Mapping)
Community Engagement (Scientific Literacy & Clinical Trials Engagement)
Better Clinical Care (Delivery & Cost-Effectiveness)

The Stakeholders Group has published this work.

In Stakeholders Group, in partnership with ICE-HBV, published the Hepatitis Commodities Access Systems & Cost Mapping resource. The mapping aims to increase awareness and information on cost and procurement within the hepatitis community, in order to increase access to viral hepatitis medicines and technologies in low-and-middle income countries, including HBV birth-dose vaccine, HBV treatment and HCV cure uptake

The Group is co-chaired by Timothy Block (Hepatitis B Foundation), Veronica Miller (HBV Forum) and Ulrike Protzer (DZIF).

Current Members:

Adepeju Gbemi Hameed, SEHAM Healthcare Foundation
Alex Ng, Bill and Melinda Gates Foundation (Beijing)
Alioune B. Coulibaly, Mali Health and Development Association APSAD/MALI
Amish Laxmidas, UNITE – Parliamentarians Network to End HIV/AIDS, Viral Hepatitis and Tuberculosis
Andrew Ball, WHO
Anna Kramvis, University of the Witwatersrand
Benjamin Cowie, WHO Collaborating Centre for Viral Hepatitis at Doherty Institute
Brian McMahon, World Indigenous Peoples’ Conference on Viral Hepatitis
Camilla Picchio, Barcelona Institute for Global Health
Capucine Penicaud, ICE-HBV + EndHep2030
Carla Coffin, Canadian Hepatitis B Network
Carol L. Brosgart, Independent
Cary James, The World Hepatitis Alliance
Cecil K. Dovia, Cedaku Foundation/Ghana Health Centre
Chari Cohen, Hepatitis B Foundation
Chris Muñoz, Yellow Warriors Society Philippines
Christian Bréchot, Global Virus Network
Christian Ramers, Clinton Health Access Initiative
Craig McClure, Clinton Health Access Initiative
David Hutton, University of Michigan
Dee Lee, Inno Community Development China
Elena Ivanova, FIND
Elisabeth Page, Canadian Institutes for Health Research – III
Emma Day, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)
Fatou Fall, Hôpital Principal de Dakar
Fernando Contreras, ALEH
Fernando Cairo, Asociación Argentina para el Estudio de las Enfermedades del Hígado (AAEEH)
Finlay Macrae, World Gastroenterology Organization
François Dabis, ANRS
Francesco Marinucci, FIND
Feank GJ Cobble’s, Amsterdam Institute for Global Health and Development
Gail Matthews, Kirby Institute
George Kalamitsis, Prometheus
Giten Khwairakpam, TreatAsia
Gregory Dore, Kirby Institute
Harry Janssen, International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)
Homie Razavi, CDA Foundation
Jack Wallace, Burnet Institute/CEVHAP
Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona
Jennifer Johnston, CEVHAP

Jessica Weber, The Forum for Collaborative Research
Jinlin Hou, Nanfang Hospital, Southern Medical University
John Ward, Task Force for Global Health
Jördis Ott, HZI
Kevin Marriott, Hepatitis Australia
Lewis Roberts, Mayo Clinic
Lindsay Hiebert, Task Force for Global Health and Coalition for Global Hepatitis Elimination
Liudmyla Maistat, Medicines Patent Pool (MPP)
Manal El-Sayed, Ain Shams University
Margaret Hellard, Burnet Institute
Margaret Littlejohn, Australian Centre for Hepatitis Virology
Marinela Debu, ELPA
Marko Korenjak, ELPA
Massimo Levrero, ICE-HBV + ANRS
Maud Lemoine, MRC Gambia/Prolifica
Maureen Kamische, Hepatitis B Foundation
Mehlika Toy, Asian Liver Centre at Stanford University
Michael Ninburg, Hepatitis Education Project
Nick Walsh, Monash University
Niklas Luhmann, WHO
Noémi Tousignant, University College London
Patricia Vélez-Möller, Asociación Guatemalteca del Hígado
Peter Revill, ICE-HBV + Doherty Institute
Philippa Easterbrook, WHO
Ponsiano Ocama, Makerere University School of Medicine
Rajen Koshi, National Institute of Allergy and Infectious Diseases
Raquel Peck, World Hepatitis Alliance
Rosmawati Mohammed, CEVHAP
Saeed Hamid, CEVHAP
Sami Stewart, ASHM
Samuel So, Asian Liver Centre at Stanford University
Sarah Haycock-Jacobs, Canadian Hepatitis B Network
Sean Regan, Clinton Health Access Initiative
Sébastien Morin, Medicines Patent Pool (MPP)
Silvana Lesidrenka
Su Wang, World Hepatitis Alliance
Timothy Block, Hepatitis B Foundation
Timothy B Hallett, Imperial College
Thomas Tu, HepBCommunity
Ulrike Protzer, DZIF
Veronica Miller, HBV Forum
Ventzislava Petrov-Sanchez, ANRS
Victoria Grandsoult, UNITE – Parliamentarians Network to End HIV/AIDS, Viral Hepatitis and Tuberculosis
Wangsheng Li, EndHep2030